Researchers from the University of Cologne, the German Center for Infection Research (DZIF), and the Broad Institute of Harvard and MIT present a remarkable clinical case in the New England Journal of
The Cologne-based research project "INNOPAK", which focuses on developing innovative precision antibodies against infections with antibiotic-resistant Pseudomonas aeruginosa-bacteria, will receive
When the bacterial pathogen Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to human cells, invade them, and form so-called biofilms. LecA thus plays a
In the future, antibodies against the virulence factors of Pseudomonas aeruginosa may serve as an alternative to antibiotics. DZIF scientists at University Hospital Cologne have been awarded the 2025
Pseudomonas aeruginosa is a multidrug-resistant bacterium that can cause life-threatening infections, such as sepsis and pneumonia. One of the key weapons used by this bacterium is the type III secretion system (T3SS), which contains the protein PcrV. Researchers at the DZIF discovered that patients ...
A balanced gut microbiome not only contributes to digestion, but is also an important protective factor against infections. Researchers at the Helmholtz Centre for Infection Research (HZI) led by Prof
An international research group led by scientists of the German Center for Infection Research (DZIF) at the Helmholtz Centre for Infection Research (HZI) has discovered a promising new drug candidate
